Exelixis' Cabometyx successor misses primary endpoint in CRC trial
Exelixis' experimental successor to Cabometyx missed its primary endpoint in a colorectal cancer trial, even as the FDA reviews a broader approval.
Exelixis
Profile of Exelixis created from news harvest. To be enriched by user.
Company Info
Sector:Oncology / Small Molecule
Headquarters:Alameda, California, USA
Founded:1994
Website:www.exelixis.com/
Clinical Development Pipeline
Undisclosed
Target: TBDRecent News
Leadership Team
Michael M. Morrissey
Chief Executive Officer